猫源支气管败血波氏杆菌灭活疫苗的研制与效力评价
本研究从临床分离株中筛选出对健康猫致病的E20株(ID50=4.64×10^8 CFU),以0.2%甲醛灭活并配以GEL 02佐剂制成灭活疫苗BbIV-E20。10周龄幼猫间隔14天皮下免疫两次,二免后21天以4×10^9 CFU E20株鼻内攻毒;疫苗安全,首免后14天100%血清转阳(IgG滴度≥1:128),攻毒后获100%临床保护,攻毒后无症状且排菌和组织载菌量显著降低。
要点
- BbIV-E20灭活疫苗在猫体内安全性良好。
- 首免后14天100%猫血清转阳,IgG滴度≥1:128。
- 攻毒后获100%临床保护,排菌与组织载菌量显著减少。
核心结论
- BbIV-E20灭活疫苗高度安全,对猫支气管败血波氏杆菌感染提供强保护免疫。
研究设计与样本
- 从临床分离株中筛选出E20株(ID50=4.64×10^8 CFU),以0.2%甲醛灭活并配GEL 02佐剂制成BbIV-E20。
- 10周龄幼猫间隔14天皮下免疫两次,二免后21天以4×10^9 CFU E20株鼻内攻毒。
主要发现
- BbIV-E20在体内安全性良好。
- 首免后14天疫苗组100%血清转阳,IgG滴度≥1:128。
- 攻毒后BbIV-E20提供100%临床保护。
- 与PBS对照组出现严重宏观和微观呼吸道病变相比,免疫猫无症状。
- 免疫猫排菌大幅减少,肺、心、肝及外周血组织载菌量显著降低。
临床怎么用
- 该疫苗基于亚洲代表性分离株,为猫细菌性呼吸道疾病防控提供候选工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bordetella bronchiseptica is a primary feline respiratory pathogen urgently requiring effective vaccines. This study characterizes a highly pathogenic Chinese isolate to establish a feline infection model and systematically evaluate a novel inactivated vaccine. METHOD: Strain E20, selected from clinical isolates, is pathogenic to healthy cats (ID50 = 4.64 × 108 CFU), was formulated into an inactivated vaccine (BbIV-E20) using 0.2% formaldehyde and GEL 02 adjuvant. Ten-week-old kittens received two subcutaneous immunizations 14 days apart. At 21 days post-booster, felines were intranasally challenged with 4 × 109 CFU of strain E20. RESULTS: BbIV-E20 exhibited an excellent in vivo safety profile. Vaccinated felines achieved 100% seroconversion (IgG titers ≥1:128) by 14 days post-primary immunization. Post-challenge, BbIV-E20 conferred complete (100%) clinical protection. Compared to PBS controls-which developed severe macroscopic and microscopic respiratory lesions-immunized cats remained asymptomatic, displaying drastically reduced bacterial shedding and significantly minimized bacterial burdens across pulmonary, cardiac, hepatic, and peripheral blood tissues. CONCLUSIONS: Derived from a representative Asian isolate, BbIV-E20 is highly safe and provides robust protective immunity against feline B. bronchiseptica infection, establishing a solid foundation for the prevention and control of feline bacterial respiratory diseases.
引用
- Li Y, Dong X, Yang A, et al. Development and efficacy evaluation of an inactivated Bordetella bronchiseptica vaccine in cats. Vaccine. 2026. PMID: 42217448. doi:10.1016/j.vaccine.2026.128778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。